Xentria Advances Pulmonary Sarcoidosis Drug Candidate Following FDA Consultation

Clinical-stage biotech Xentria has received positive FDA feedback regarding its XTMAB-16 program for pulmonary sarcoidosis, clearing regulatory pathways for continued clinical development and potential next-phase trials.

1 Sept, 11:00 — 1 Sept, 11:00

Post Share

Sources

Showing 1 of 1 sources

morningstar12h ago

Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback - Morningstar

Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback Morningstar

Read full article →

Xentria Advances Pulmonary Sarcoidosis Drug Candidate Following FDA Consultation

Sources

Xentria Advances XTMAB-16 Clinical Development in Pulmonary Sarcoidosis Following FDA Feedback - Morningstar

Related Stories

Dell Raises Full-Year Forecast After Strong AI-Driven Earnings

EU Tourism Data Shows Divergent Trends as Cyprus Suffers Steepest Decline

Rising Oil Prices Drive Up Bond Yields and Trigger Equity Sell-Offs

Global Bond Sell-Off Drives Up Yields Amid Market Volatility